FDA gave its blessing based on a trial showing it offered breast cancer patients an extra 5.5 months of "progression-free survival," time when their tumors weren't growing.
FDA是基于阿瓦斯丁可以让患者的肿瘤在5个半月内都不增长的研究，批准了阿瓦斯丁的使用许可。
This study aims to analyze the factors that influence the progression-free survival time of PCa patients after endocrine therapy in an attempt to improve the prognosis of the disease.
目的：前列腺癌内分泌治疗后发现进展速度存在较大差异，为了改善其预后，本文探讨前列腺癌内分泌治疗后无进展生存期的影响因素。
This study aims to analyze the factors that influence the progression-free survival time of PCa patients after endocrine therapy in an attempt to improve the prognosis of the disease.
目的：前列腺癌内分泌治疗后发现进展速度存在较大差异，为了改善其预后，本文探讨前列腺癌内分泌治疗后无进展生存期的影响因素。
应用推荐